Progestogen for treating threatened miscarriage
Open accessThe DOI matches its OpenAlex record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Miscarriage is a common complication encountered during pregnancy. It is defined as spontaneous pregnancy loss before 20 weeks' gestation. Progesterone's physiological role is to prepare the uterus for the implantation of the embryo, enhance uterine quiescence and suppress uterine contractions, hence, it may play a role in preventing rejection of the embryo. Inadequate secretion of progesterone in early pregnancy has been linked to the aetiology of miscarriage and progesterone supplementation has been used as a treatment for threatened miscarriage to prevent spontaneous pregnancy loss. This update of the Cochrane Review first published in 2007, and previously updated in 2011, investigates the evidence base for this practice. OBJECTIVES: To determine the efficacy and the safety of progestogens in the treatment of threatened miscarriage. SEARCH METHODS: We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) (8 August 2017) and reference lists of retrieved trials. SELECTION CRITERIA: Randomised, quasi-randomised or cluster-randomised controlled trials, that compared progestogen with placebo, no treatment or any other treatment for the treatment of threatened miscarriage in women carrying singleton pregnancy. DATA COLLECTION AND ANALYSIS: At least two review authors assessed the trials for inclusion in the review, assessed trial quality and extracted the data and graded the body of evidence. MAIN RESULTS: We included seven trials (involving 696 participants) in this update of the review. The included trials were conducted in different countries, covering the full spectrum of the World Bank's economic classification, which enhances the applicability of evidence drawn from this review. Two trials were conducted in Germany and Italy which are high-income countries, while four trials were conducted in upper-middle income countries; two in Iran, one in Malaysia and the fourth in Turkey, and the seventh trial was conducted in Jordan, which is a lower-middle income country. In six trials all the participants met the inclusion criteria and in the seventh study, we included in the meta-analysis only the subgroup of participants who met the inclusion criteria. We assessed the body of evidence for the main outcomes using the GRADE tool and the quality of the evidence ranged from very low to moderate. Downgrading of evidence was based on the high risk of bias in six of the seven included trials and a small number of events and wide confidence intervals for some outcomes.Treatment of miscarriage with progestogens compared to placebo or no treatment probably reduces the risk of miscarriage; (risk ratio (RR) 0.64, 95% confidence interval (CI) 0.47 to 0.87; 7 trials; 696 women; moderate-quality evidence). Treatment with oral progestogen compared to no treatment also probably reduces the miscarriage rate (RR 0.57, 95% CI 0.38 to 0.85; 3 trials; 408 women; moderate-quality evidence). However treatment with vaginal progesterone compared to placebo, probably has little or no effect in reducing the miscarriage rate (RR 0.75, 95% CI 0.47 to 1.21; 4 trials; 288 women; moderate-quality evidence). The subgroup interaction test indicated no difference according to route of administration between the oral and vaginal subgroups of progesterone.Treatment of preterm birth with the use of progestogens compared to placebo or no treatment may have little or no effect in reducing the rate of preterm birth (RR 0.86, 95% CI 0.52 to 1.44; 5 trials; 588 women; low-quality evidence).We are uncertain if treatment of threatened miscarriage with progestogens compared to placebo or no treatment has any effect on the rate of congenital abnormalities because the quality of the evidence is very low (RR 0.70, 95% CI 0.10 to 4.82; 2 trials; 337 infants; very-low quality evidence). AUTHORS' CONCLUSIONS: The results of this Cochrane Review suggest that progestogens are probably effective in the treatment of threatened miscarriage but may have little or no effect in the rate of preterm birth. The evidence on congenital abnormalities is uncertain, because the quality of the evidence for this outcome was based on only two small trials with very few events and was found to be of very low quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
Harbord, R. M., Egger, M., & Sterne, J. A. C. (2006) · Statistics in Medicine · doi:10.1002/sim.2380 · Cited by 2,267
Prevention of recurrent preterm delivery by 17 alpha–hydroxyprogesterone caproate
Meis, P. J., Klebanoff, M., Thom, E., Dombrowski, M. P., Sibai, B., Moawad, A. H., Spong, C. Y., Hauth, J. C., Miodovnik, M., Varner, M. W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035140 · Cited by 1,555
Metwally, M., Ong, K. J., Ledger, W. L., & Li, T. C. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.07.1290 · Cited by 539
A Randomized Trial of Progesterone in Women with Recurrent Miscarriages
Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., Gupta, P., Dawood, F., Koot, Y. E. M., Bender Atik, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504927 · Cited by 312
Saraswat, L., Bhattacharya, S., Maheshwari, A., & Bhattacharya, S. (2010) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2009.02427.x · Cited by 228
Cohain, J. S., Buxbaum, R. E., & Mankuta, D. (2017) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-017-1620-1 · Cited by 141
Randomised trial comparing expectant with medical management for first trimester miscarriages
Nielsen, S., Hahlin, M., & Platz‐Christensen, J. (1999) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08401.x · Cited by 126
Genetic Factors as a Cause of Miscarriage
Suzumori, N., & Sugiura-Ogasawara, M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793176302 · Cited by 118
Cited by
State-of-the-science of endocrine disrupting chemicals, 2012
Bergman, Å., Heindel, J., Jobling, S., Kidd, K., & Zoeller, R. T. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.03.020 · Cited by 1,388
Dimitriadis, E., Menkhorst, E., Saito, S., Kutteh, W. H., & Brosens, J. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00228-z · Cited by 702
Magon, N., & Kumar, P. (2012) · Nigerian Medical Journal · doi:10.4103/0300-1652.107549 · Cited by 271
Early risk factors for miscarriage: a prospective cohort study in pregnant women
Arck, P. C., Rücke, M., Rose, M., Szekeres-Bartho, J., Douglas, A. J., Pritsch, M., Blois, S. M., Pincus, M. K., Bärenstrauch, N., Dudenhausen, J. W., et al. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60300-8 · Cited by 219
A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy
Coomarasamy, A., Devall, A. J., Cheed, V., Harb, H., Middleton, L. J., Gallos, I. D., Williams, H., Eapen, A. K., Roberts, T., Ogwulu, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813730 · Cited by 197
Metadata
- Authors
- Wahabi, H., Fayed, A. A., Esmaeil, S. A., & Alzeidan, R. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Elsevier BV
- Published
- 2011-12-05
- Volume
- 8
- Issue
- 12
- Pages
- CD005943-CD005943
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2119795795
- Cited by
- 148
- References
- 8
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progestogen for treating threatened miscarriage. https://app.cochat.ai/papers/10.1002/14651858.cd005943.pub4
- The paper
- Wahabi, H., Fayed, A. A., Esmaeil, S. A., & Alzeidan, R. A. (2011). Progestogen for treating threatened miscarriage. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005943.pub4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.